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SUMMARY One hundred and eighty nine patients with primary biliary cirrhosis were entered into
a double blind, placebo controlled randomised trial starting in January 1978 to assess the
therapeutic value of d-penicillamine 1200 mg daily. Eighteen of the 98 patients receiving
d-penicillamine and 22 of the 91 placebo. treated patients died during the study. Thirty six per
cent of those on d-penicillamine and 8% of those on placebo were withdrawn from the study. No
difference in overall survival was noted between the two groups of patients whether the results
were analysed for the entire period of observation or only during the period in which the patients
were receiving therapy. The mortality rate of those receiving d-penicillamine in histological stage
I to II, however, was one third of that of the placebo group although this difference did not reach
statistical significance. Using the occurrence rate ratio as the statistical method of analysis, no
effect of d-penicillamine was noted on any clinical, biochemical or histological features
examined, except the serum alanine aminotransferase activity which was greater in those on
active treatment. In this trial we have been unable to establish any therapeutic benefit from the
drug.
A number of therapeutic agents have been used in
an attempt to control the underlying lesion in
primary biliary cirrhosis. Corticosteroids have been
associated with improvement of serum liver function
tests,1 2 but no controlled trial has been carried out
and their bone thinning properties are likely to
exacerbate the osteoporosis associated with the
disease.3 In one large multicentre placebo
controlled trial azathioprine appeared to have some
effect although the difference in survival did not
reach statistical significance.4 d-penicillamine was
used initially because of its cupruretic effect5 and its
ability to remove immune complex-like activity from
the serum of such patients.6 It is now apparent,
however, that the drug has other properties which
may affect the course of primary biliary cirrhosis,
such as its ability to interfere with collagen
metabolism7 and to reduce the number of circulating
T lymphocytes.8 After the publication of a prelimi-
nary study suggesting that survival was improved,9 a
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number of controlled trials were set up, but the
results to date are conflicting.1>13 We report here
the results of an international, double blind, placebo
controlled trial set up in 1977.
Methods
PATIENTS
Criteria for entry into the trial included a clinical
and histological picture compatible with that of
primary biliary cirrhosis, the liver biopsy being
taken within six months before entry and a serum
alkaline phosphatase more than twice the upper
limit of normal in the absence of evidence of
extrahepatic biliary obstruction. Those patients who
had been taking azathioprine within six months were
excluded from the study. Informed consent was
obtained before entry into the study and approval
was also given by the ethical committee in each
hospital.
Patients were entered regardless of age or histo-
logical stage of the disease at diagnosis. Random-
isation was performed separately for each Centre
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(London, Barcelona, Copenhagen) and for each
sex. Dosage was one tablet daily (containing either
d-pencillamine 300 mg or lactose 50 mg), being
increased by one tablet each fortnight until a
maximum of four tablets daily were taken. In
addition, all patients were given pyridoxine 20 mg
daily. Patients were withdrawn from the trial if they
developed signs or symptoms of possible side-effects
from d-penicillamine, specifically thrombocytopenia
(less than 60x 109/l), neutropenia (less than 2x 106/1)
or proteinuria (greater than 2 g daily).
Clinical assessment was carried out at entry and at
six monthly intervals. This included an estimation of
the patient's well-being, as assessed by the incapaci-
tation index described in detail elsewhere.4 Blood
was taken for estimation of standard liver function
tests, serum immunoglobulins and autoantibodies.
Each patient underwent a liver biopsy within six
months of entry into the trial and at annual
intervals. The biopsy specimens were assessed by a
histopathologist (BP), without knowledge of
treatment received or clinical condition of the
patient.
STATISTICAL ANALYSIS
The death rate and the occurrence rate of clinical,
serological, and histological features in patients who
did not have those features at entry into the trial
were analysed by the life table method using the log
rank test for comparison of groups.14 This method
was used because it allows for incomplete follow up
whether because of death, withdrawal, or loss from
follow up. The occurrence rate ratio (or relative
risk) was calculated as (OPEN/EPEN)/(OPLAc/EPLAC)
when OPEN is the number of patients observed to
develop a particular abnormal feature on d-penicil-
lamine and EPEN is the estimated number of patients
in the d-penicillamine treated group expected to
develop that feature. OPLAC and EPLAC are the
corresponding values for the placebo treated group.
The calculation of EPEN and EPLAC uses the
temporal pattern of occurrence and assumes that the
rate of occurrence is the same in the two groups;4
hence a ratio of 0-5 means that the feature is half as
likely to occur in the treated group as in the placebo
group. Because this method requires that
continuous variables, such as serum bilirubin, are
analysed as discrete ones, we have arbitrarily chosen
to define an occurrence if the value falls outside the
'abnormal' fifteenth percentile of the distribution of
that variable at entry. Thus, with respect of serum
bilirubin, an occurrence was deemed to occur when
the serum concentration exceeded 90 ,umol/l; and
other limits are given in Table 1. Analyses were
performed both for the total period of observation
and up to the time of withdrawal.
Results
Between January 1978 and December 1982 when
this analysis was performed, 189 patients had been
entered into the trial. Of the total, 87 had been
followed in London, 65 in Copenhagen and 37 in
Barcelona. Analysis of the clinical, biochemical,
serological, and histological data for patients in the
d-penicillamine treated and placebo treated groups
were similar at entry (Table 2). Nine patients
receiving d-penicillamine were asymptomatic at the
time of entry into the trial and eight in the placebo
group.
In the d-penicillamine treated group 35 were
withdrawn from treatment, because of rash (9),
Table 1 Effect of d-penicillamine on the occurrence rate of clinical, biochemical and histologicalfeatures after entry into
the trial
Observed/expected ratio
Occurrence rates ratio p Value
Variable d-penicillamine Placebo (95% confidence limits) (2ct)
Clinical features
Pruritus/cholestyramine 16/13-03 26/28 97 1-37 (077-2-42) 0-78
Ascites/diuretics 14/15-74 21/19 26 0-82 (0-451-50) 0-52
GI bleeding 4/4-81 8/7-19 0-75 (0.26-2.14) 0-59
Incapacitation index >25 22/22 74 24/23 26 0-94 (0.54-1-64) 0-83
Biochemistry
Bilirubin >90,umol/l 7/10-30 14/10 70 0.52 (0.21-1-26) 0-15
Albumin <30 g/l 13/14-80 16/14 20 0-78 (0 381-61) 0-50
IgM >6-9 g/l 15/11-14 -14/17 86 1.72 (0.91-3-25) 0 09
Histology
Stage III/IV 21/17-75 13/16 26 1-48 (0-77-2-86) 0-24
StageIV 10/11 35 13/16-23 0.79(0-35-1-76) 0-56
Bilirubin 1 ,umol/l = 0-02 mg/dl. Albumin 1 g/l = 0 1 g/dl.
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Table 2 Clinical, median biochemical, serological and
histological details ofpatients int the placebo and
d-penicillamine groups at entry into the trial
Placebo d-penicillamine
Cases (no) 91 98
Males (%) 7 9
Median duration of history (years) 1-6 1-8
Frequency ofclinicalfindings
Pruritus 63% 59%
Jaundice 46% 37%
Xanthoma 22% 17%
GI bleeding 17% 22%
Ascites 7% 13%
Liverfunction tests (normal range)
Bilirubin (3-20 Amol/l) 21-0 23-9
Alkaline phosphatase (3-85 IU/l) 504 502
Alanine aminotransferase (7-40 IU/l) 72 80
Cholesterol (38-3 mmol/l) 6-5 6-3
Albumin (35-50 g/l) 35-2 35-4
IgM (0-5-2 g/l) 3-5 3-6
Mitochondrial antibodies % 88 85
Liver histology
Stage I 15% 12%
Stage II 37% 40%
Stage III 21% 24%
Stage IV 27% 24%
Bilirubin 1 ,umol/l = 0-02 mg/dl. Albumin 1 g/l = 0-1 g/dl.
proteinuria (5), thrombocytopenia. (4), gastro-
intestinal upset (4), rash and arthralgia (3), non-
compliance (3) and one each for leucopenia,
asthma, pemphigoid, ageusia, psychosis, and
palpitations. The final patient was withdrawn when
a liver transplant was considered to be indicated.
Seven patients were withdrawn from the placebo
treated group on account of headaches (2), gastro-
intestinal upset (1), proteinuria (1), neurological
complications (1), non-compliance (1) and liver
transplantation (1). Significantly more patients
withdrew from the treatment group than the control
group (p<0O0001) (Table 3).
No significant difference in overall survival
between patients in the placebo and d-penicillamine
treated groups was observed (Figure); this was
independent of whether the total observation period
or only the time up to withdrawal was used for
calculation of the curves. The p values are calculated
after stratification according to each centre, even
though the effect of d-penicillamine on survival was
not significantly different in the three centres.
Separation of the patients into early (histological
stage I/II) and late (stage III/IV) showed an
apparent beneficial effect on survival when
d-penicillamine was used in the early stages of the
disease, the mortality rate being one third of that
seen in the placebo treated group. The difference,
however, did not reach statistical significance
(p=015). None of the patients asymptomatic at
entry died during the course of the trial. In patients
with late stage disease the death rates were nearly
identical in the two groups (p=0.99). Survival in
those patients who were able to tolerate the full dose
of d-penicillamine was similar to survival in the
control group.
The occurrence rate for gastrointestinal bleeding,
pruritus (or the need for cholestyramine) and ascites
(or use of diuretics) was similar in both groups. The
only difference with respect to liver funstion tests,
biochemical, and serological findings was that the
use of d-penicillamine was associated with a signifi-
cant increase in serum alanine aminotransferase,
above 136 IU/l. There was no difference in the rate
of histological progression as assessed from the
Table 3 Reason for withdrawalfrom the trial and median time of withdrawal after institution of treatment
d-penicillamine Placebo
Cause No Time (Range) No Time (Range)
Rash 9 4 months (13 days-7 months)
Proteinuria 5 8 months (3 days-24 months) 1 7 months
Thrombocytopenia 4 11 months (1-19 months)
Rash and arthralgia 3 3 months (1-17 months)
Gastrointestinal upset 4 11 months (2 weeks-18 months) 1 7 months
Leucopenia 1 24 months
Asthma 1 31 months
Pemphigoid 1 12 months
Ageusia 1 8 months
Psychosis 1 1 week
Palpitations 1 3 months
Liver transplantation 1 11 months 1 7 months
Non-compliance 3 1 month (3 days-8 months) 1 2 weeks
Neurological complications 1 2 months
Headaches 2 31 months (3-4 months)
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Figure Cumulative survivalfor patients with primary biliary cirrhosis receiving either placebo or d-penicillamine for
(a) total period ofobservation (ORR=091, p=0-78) and (b) during period of receiving therapy (ORR=0-98, p=0.96).
Number ofpatients observed in each group represents the number ofpatients alive at that time.
serial biopsies obtained and d-penicillamine did not
appear to prevent progression of the disease from
early to late histological stages (Table 1). Analysis
of the serological and histological findings in the two
groups based on the time until withdrawal gave
results similar to those in Table 1, which are based
on the entire period of observation.
Forty patients had died by the time of analysis
(Table 4). Of the 18 who died in the d-penicillamine
treated group, 16 were associated with liver disease
Table 4 Causes ofdeath in patients entered into the trial
Placebo d-penicillamine
Related to liver disease
Liver failure 10 10
Liver failure and GI bleeding 4 4
GI bleeding 2 1
Bacterial peritonitis 1 -
Hepatocellular carcinoma 1 1
Unrelated to liver disease
Renal failure 1 -
Asthma - 1
Bronchial cancer 1 -
Fractured femur 1 -
Cardiovascular disease 1 1
TOTAL 22 18
and the remaining deaths were because of pre-
existing asthma and cardiovascular disease. Of the
22 deaths in the placebo treated group, 18 were
associated with liver disease and the remainder were
because of cardiovascular disease, renal failure,
bronchial carcinoma, and following a fractured
femur. There was no significant difference in the
number of deaths or distribution of the main causes
of death between the two groups.
Discussion
The use of the occurrence rate ratio to analyse the
effect of treatment with d-penicillamine on the
survival, clinical, and serological variables was
chosen because it is a more effective discriminant of
the population trend than measuring the percentage
increase or decrease of the variables with time. For
example, an increase in serum bilirubin from 8-12
,umol/l will show the same percentage increase in
levels as that from 80 to 120 ,umol/l. In contrast,
with the use of the occurrence rate ratio, only the
latter example will be recorded as an 'event' or
occurrence. Yet clearly the implications on the
natural history of the disease are quite different:
levels of serum bilirubin in the normal range are
indicative of a good prognosis15 whereas the rising
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levels indicate a poor prognosis and advancing
disease.'6 The other advantage of this method of
analysis is that it allows for incomplete follow-up of
patients for any cause. This method of analysis,
however, does require continuous variables to be
treated as discrete ones. The arbitrary use of the
fifteenth percentile allows a reasonable number of
patients to have 'events' recorded. Comparable
findings, however, were obtained when different
cut-off figures were used. In this report we have
analysed results for patients up to the time of
withdrawal as well as patients followed during the
entire period of the trial. The former analysis may
be biased if the patients who were withdrawn from
the trial, usually because of drug-related side
effects, differ in prognosis from those not with-
drawn. Analysis based on the intention to treat may
be more valid although the effect of a short and not
maintained course of d-penicillamine on the natural
history of a disease lasting many years may be
questionable. Nonetheless, both methods of analysis
gave very similar results.
The various trials of d-penicillamine reported to
date differ both in trial design and in dosage used.
The largest study is that from the Mayo Clinic"3 in
which patients were given placebo or d-penicil-
lamine 1000\mg. There was an associated improve-
ment in survival at all stages of the disease and
progression of liver histology from early to late
stages was reduced. One death was attributed to
side-effects from the drug. In contrast, Epstein et a19
used d-penicillamine at a daily dose of 600 mg and
found no effect on those treated at early stages,
although there was a significant improvement in
those treated in histological stages III and IV after
18 months of treatment. In a study carried out in
Boston15 d-penicillamine was not associated with
improvement of any variable measured; indeed,
those on active treatment had a slightly worse
prognosis. In Newcastle, Bassendine and her
colleagues" were able to show that, at a daily dose
of 1000 mg, there was an improvement in serum
transaminase and immunoglobulins, while at lower
doses (250 mg daily) the improvement was only
temporary. Survival was not affected compared with
placebo in either group. In Sheffield it was found
that in doses up to 875 mg daily there was
improvement in liver histology, although no effect
on survival was found.'2
To what extent these differences in results are
because of selection of patients or different popula-
tion studied is not clear. It is now becoming
apparent that the syndrome of primary biliary
cirrhosis covers a wide spectrum of disease activity.
It may be possible to identify a subgroup of such
patients whose disease activity may be controlled by
long term therapy with d-penicillamine, although
such identification was not possible in our trial. The
mode of action of the drug in primary biliary
cirrhosis, if any, is not clear. Although introduced
because of its ability to reduce liver copper content
and reduce the levels of circulating immune
complexes. It is probable that the liver copper is not
hepatotoxic in primary biliary cirrhosis: 17 any
improvement noted in patients on treatment with
d-penicillamine may not be associated with a
reduction in hepatic copper.18 Reductions in levels
of circulating immune complexes is another prob-
ability, but the importance of immune complexes,
and indeed their existence in primary biliary
cirrhosis, has recently been questioned.19 d-penicil-
lamine and its use requires that the patient attends
frequently for blood and urine monitoring. Side
effects both in this trial and in the trials reported
occurred in up to 30% of patients.
The maximum period of follow up of patients in
the trial is short in comparison with the natural
history of the disease. Accordingly, the confidence
limits of our results are not very narrow and it is still
possible that significant effects on survival will be
noted, perhaps in subgroups, when follow-up is
longer. For these reasons, it is intended to continue
the study although no new patients will be added.
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